Effects of CART19 Cells in Patients with Certain Blood Cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase I open-label, single-arm study evaluating the safety and efficacy of autologous CAR19 T lymphocytes in adult patients with relapsed or refractory CD19+ Non-Hodgkin's Lymphoma or B-cell Acute Lymphoblastic Leukemia. The study will involve up to 24 participants who will undergo a lymphodepleting conditioning regimen followed by a single dose of CART19 cells. The dose will be escalated in consecutive patients using an accelerated titration design to determine the maximum tolerated or feasible dose for further studies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patient with refractory or relapsing CD19 positive B-ALL or B-NHL defined as:

   1. B-ALL refractory to treatment or in the second or subsequent relapse (hematological OR molecular), OR
   2. B-NHL refractory to treatment or in first relapse ineligible for autologous stem cell transplantation (ASCT) or in second to fourth relapse, OR
   3. B-ALL or B-NHL relapsing after autologous or allogeneic hematopoietic cell transplantation (HCT).
2. CD19 expression on malignant cells confirmed by flow cytometry or by immunohistochemistry.
3. Age ≥18 years and ≤ 80 yearss.
4. Patient able to understand and sign informed consent.
5. Women of child-bearing potential: negative pregnancy test at enrolment (PSV) and at Visit 1.

General Exclusion Criteria:

1. Known hypersensitivity to any component of the Investigational Medicinal Product (IMP).
2. Autologous or allogeneic HCT in 3 months prior to IMP administration.
3. Severe, uncontrolled active infection.
4. Life expectancy \< 6 weeks.
5. Parenchymal central nervous system involvement.
6. Respiratory insufficiency (need for oxygen therapy).
7. Significant liver impairment: bilirubin \> 50 µmol/L, AST or ALT \> 4times normal upper limit.
8. Acute kidney injury with serum creatinine \> 180 µmol/L, oliguria or need for acute dialysis.
9. Heart failure with EF \< 30% by echocardiography.
10. Presence of active grade 3-4 acute GvHD.
11. Serious uncontrolled neurological comorbidity.
12. Vaccination with live virus vaccines in the 4 weeks before IMP administration and within 90 days after the IMP dose.
13. Women: pregnancy or breast-feeding.
14. Subjects of fertile age, unless permanent sexual abstinence is their lifestyle choice:

    * female patients of childbearing potential not willing to use a highly effective method of contraception during the study,
    * male patients whose sexual partner(s) are women of childbearing potential who are not willing to use a highly effective method of contraception during the study.

Exclusion criteria to Procurement of IMP manufacture starting material

1. Severe uncontrolled active infection.
2. Positive test results for HIV1/2, Hepatitis B/C and lues.
3. Concurrent or recent prior therapies before apheresis:

   * Autologous or allogeneic hematopoietic cell transplantation within 12 weeks.
   * Clofarabine, Fludarabine, Alemtuzumab within 8 weeks.
   * Donor lymphocyte infusions within 4 weeks.
   * Pegylated asparaginase within 4 weeks.
   * Maintenance chemotherapy within 2 weeks.
   * Long-acting Granulocyte Colony Stimulating Factor (G-CSF) within 2 weeks.
   * Vincristine within 2 weeks.
   * Intrathecal methotrexate within 1 week.
   * Granulocyte Colony Stimulating Factor (G-CSF) within 5 days.
   * Therapeutic dose of corticosteroids within 3 days.
   * Short-acting cytostatics within 3 days

Exclusion criteria to IMP administration

1. Severe, uncontrolled active infections.
2. Life expectancy \< 6 weeks.
3. Parenchymal central nervous system involvement
4. Respiratory insufficiency (need for oxygen therapy).
5. Significant liver impairment: bilirubin \> 50 µmol/L, Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) \> 4times normal upper limit.
6. Acute kidney injury with serum creatinine \> 180 µg/L, oliguria or need for acute dialysis.
7. Heart failure with Ejection Fraction (EF) \< 30% by echocardiography.
8. Presence of active grade 3 - 4 acute GvHD
9. Serious uncontrolled neurological comorbidity.

Where it's running

• Institute of Hematology and Blood Transfusion, Czech Republic
  Prague, Czechia Recruiting

Study contacts

• Principal investigator: Jan Vydra — Institute of Hematology and Blood Transfusion, Czech Republic
• Study coordinator: Jan Vydra
• Email: jan.vydra@uhk.cz
• Phone: +420221977182

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GN001 therapy for B-cell cancers that have come back or not responding

  This study tests GN001, a CAR T therapy created inside the body, in adults with CD19-positive relapsed or refractory B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia to see if it is safe and tolerable at different doses.

  Recruiting at 2 sites Phase 1 Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital · Kunming, Yunnan and 1 other locations · NCT07910708

• Evaluating B019 Injection for Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

  This study is testing a new injection called B019 to see if it can help people with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia feel better.

  Recruiting at 8 sites Phase 1 Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. · Beijing and 7 other locations · NCT06927466

• CD19 targeted CAR T cell therapy for children with relapsed or refractory B cell leukemia and lymphoma

  This study is testing a new CAR T cell therapy for children with tough-to-treat B cell leukemia and lymphoma to see if it can help them feel better.

  Recruiting at 14 sites Phase 1 Autolus Limited · Los Angeles, California and 13 other locations · NCT06173518

• Ronde-cel versus standard CD19 CAR T‑cell therapy for relapsed or refractory large B‑cell lymphoma

  This test sees if ronde-cel, a CAR T therapy that targets both CD19 and CD20, works better than currently used CD19 CAR T therapies for adults whose large B‑cell lymphoma returned or did not respond after first‑line treatment.

  Recruiting at 41 sites Phase 3 Lyell Immunopharma, Inc. · Gilbert, Arizona and 43 other locations · NCT07188558

• Using CD45RA Depleted Stem Cells to Prevent Infections After Transplant

  This study is testing whether using special stem cells can help patients with high-risk leukemia recover their immune system faster and prevent infections after a stem cell transplant.

  Recruiting Phase 1/2 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT06839456

• Preventing CAR-T cell toxicities with emapalumab

  This study is testing if a drug called emapalumab can help prevent side effects in people with large B-cell non-Hodgkin's lymphoma who are receiving another treatment called axicabtagene ciloleucel.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT06550141

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.